Post by HealthCare Middle East & Africa Magazine

In this week's newsletter, Kenya has introduced its Health Products & Technologies Local Manufacturing Strategy for 2026–2030, outlining a comprehensive plan to boost domestic production and enhance supply chains. Meanwhile, GSK has launched Shingrix in South Africa, making effective shingles prevention available to more adults in the region. In the Middle East, Sheikh Khalifa Medical City Ajman has achieved Level 4 PSFHI Patient Safety accreditation, signaling a strong commitment to excellence in patient-centered care. Additionally, NMC Oman has undergone a rebranding to become Numa Health under the Tawoos Healthcare Group, marking a significant shift in the regional healthcare landscape and its offerings. On a global scale, AviadoBio is expanding its licensing agreement for King's College London’s RNAi platform, which will accelerate research and development in RNAi and its therapeutic potential. In another significant move, Merck KGaA, Darmstadt, Germany is set to acquire Bio-Techne for US$11.3 billion, a major consolidation that will enhance capabilities in life sciences tools and reagents. #healthcare #biotech #pharma #manufacturing #publichealth #RNAi #patientSafety #healthtech #mergersandacquisitions #AfricaHealth